Matches in Wikidata for { <http://www.wikidata.org/entity/Q37653417> ?p ?o ?g. }
Showing items 1 to 82 of
82
with 100 items per page.
- Q37653417 description "article científic" @default.
- Q37653417 description "article scientifique" @default.
- Q37653417 description "articolo scientifico" @default.
- Q37653417 description "artigo científico" @default.
- Q37653417 description "artículu científicu espublizáu en 2016" @default.
- Q37653417 description "bilimsel makale" @default.
- Q37653417 description "scientific article published on 19 December 2016" @default.
- Q37653417 description "vedecký článok" @default.
- Q37653417 description "vetenskaplig artikel" @default.
- Q37653417 description "videnskabelig artikel" @default.
- Q37653417 description "vědecký článek" @default.
- Q37653417 description "wetenschappelijk artikel" @default.
- Q37653417 description "wissenschaftlicher Artikel" @default.
- Q37653417 description "наукова стаття, опублікована в грудні 2016" @default.
- Q37653417 description "научни чланак" @default.
- Q37653417 description "مقالة علمية نشرت في 19 ديسمبر 2016" @default.
- Q37653417 name "Safety Profile Based on Concordance of Nonclinical Toxicity and Clinical Adverse Drug Reactions for Blood Cancer Drugs Approved in Japan" @default.
- Q37653417 name "Safety Profile Based on Concordance of Nonclinical Toxicity and Clinical Adverse Drug Reactions for Blood Cancer Drugs Approved in Japan" @default.
- Q37653417 name "Safety Profile Based on Concordance of Nonclinical Toxicity and Clinical Adverse Drug Reactions for Blood Cancer Drugs Approved in Japan" @default.
- Q37653417 type Item @default.
- Q37653417 label "Safety Profile Based on Concordance of Nonclinical Toxicity and Clinical Adverse Drug Reactions for Blood Cancer Drugs Approved in Japan" @default.
- Q37653417 label "Safety Profile Based on Concordance of Nonclinical Toxicity and Clinical Adverse Drug Reactions for Blood Cancer Drugs Approved in Japan" @default.
- Q37653417 label "Safety Profile Based on Concordance of Nonclinical Toxicity and Clinical Adverse Drug Reactions for Blood Cancer Drugs Approved in Japan" @default.
- Q37653417 prefLabel "Safety Profile Based on Concordance of Nonclinical Toxicity and Clinical Adverse Drug Reactions for Blood Cancer Drugs Approved in Japan" @default.
- Q37653417 prefLabel "Safety Profile Based on Concordance of Nonclinical Toxicity and Clinical Adverse Drug Reactions for Blood Cancer Drugs Approved in Japan" @default.
- Q37653417 prefLabel "Safety Profile Based on Concordance of Nonclinical Toxicity and Clinical Adverse Drug Reactions for Blood Cancer Drugs Approved in Japan" @default.
- Q37653417 P1433 Q37653417-27E9508F-52C3-42AC-9301-5443D3983E55 @default.
- Q37653417 P1476 Q37653417-D453BDB2-14E5-41AC-90D4-237EF46A9809 @default.
- Q37653417 P2093 Q37653417-247E8C5F-1514-4D94-951C-5FB714BD7FA0 @default.
- Q37653417 P2093 Q37653417-47BCF1FD-209F-4BB8-B474-BCE9CD85B7D8 @default.
- Q37653417 P2093 Q37653417-856110D7-5B4F-45D0-A88D-6F53BB1FE589 @default.
- Q37653417 P275 Q37653417-24ecb139-4087-440b-a5ef-219fbf700766 @default.
- Q37653417 P2860 Q37653417-2265BCFC-F469-484B-B3E1-77D56DFA00B1 @default.
- Q37653417 P2860 Q37653417-2B61DD12-3074-4E98-8C44-465CE2ED34AB @default.
- Q37653417 P2860 Q37653417-318142E7-F26B-4856-BF41-758E1380EABD @default.
- Q37653417 P2860 Q37653417-580E8345-E034-40BE-8F23-2059C8E3184F @default.
- Q37653417 P2860 Q37653417-585574E8-D155-47C7-98FB-8E5152F30470 @default.
- Q37653417 P2860 Q37653417-8C42890D-B3BB-4956-B3BC-E4BF356D1F24 @default.
- Q37653417 P2860 Q37653417-AF6D4922-D923-4CF7-A538-B56AFC9FC5B6 @default.
- Q37653417 P2860 Q37653417-C0026137-551F-4429-8D2F-4AA916C43156 @default.
- Q37653417 P2860 Q37653417-CF624D30-2665-492C-846D-52AB1658EFBE @default.
- Q37653417 P2860 Q37653417-D2C37503-4850-465A-8F1D-9386E0AF813E @default.
- Q37653417 P2860 Q37653417-F496B465-6ECD-4327-B345-DF69C2D2635A @default.
- Q37653417 P304 Q37653417-1F1884DF-DC92-4105-ADAD-27DEFD31785B @default.
- Q37653417 P31 Q37653417-98BF9E59-B2CE-4C32-9514-D11847A69975 @default.
- Q37653417 P356 Q37653417-4EFF732E-8D3A-49AD-ABF7-409CD8828D33 @default.
- Q37653417 P433 Q37653417-A05D9738-6D24-458E-81E2-B29AF7B6BE33 @default.
- Q37653417 P478 Q37653417-D7EEFF02-E01D-41BD-AF94-E4FA1D2EA528 @default.
- Q37653417 P50 Q37653417-9033C4F0-9850-49ED-8D5E-414F71903B9D @default.
- Q37653417 P577 Q37653417-E75A630C-0178-46AD-98E1-5FBA9FD07179 @default.
- Q37653417 P6216 Q37653417-ac74e25e-5e98-4d7b-8a02-a58d798359f5 @default.
- Q37653417 P698 Q37653417-A674F57D-04DB-44EC-9A8A-281439F49C40 @default.
- Q37653417 P932 Q37653417-7E052054-F1AC-46FA-BB39-7D793FE4E127 @default.
- Q37653417 P356 S40268-016-0160-X @default.
- Q37653417 P698 27995532 @default.
- Q37653417 P1433 Q26842117 @default.
- Q37653417 P1476 "Safety Profile Based on Concordance of Nonclinical Toxicity and Clinical Adverse Drug Reactions for Blood Cancer Drugs Approved in Japan" @default.
- Q37653417 P2093 "Kazuyuki Saito" @default.
- Q37653417 P2093 "Shunsuke Ono" @default.
- Q37653417 P2093 "Yasuo Kodama" @default.
- Q37653417 P275 Q34179348 @default.
- Q37653417 P2860 Q33921168 @default.
- Q37653417 P2860 Q35610097 @default.
- Q37653417 P2860 Q36084990 @default.
- Q37653417 P2860 Q39391429 @default.
- Q37653417 P2860 Q40121063 @default.
- Q37653417 P2860 Q43561430 @default.
- Q37653417 P2860 Q44812410 @default.
- Q37653417 P2860 Q53242492 @default.
- Q37653417 P2860 Q55892524 @default.
- Q37653417 P2860 Q71515015 @default.
- Q37653417 P2860 Q91507932 @default.
- Q37653417 P304 "133-143" @default.
- Q37653417 P31 Q13442814 @default.
- Q37653417 P356 "10.1007/S40268-016-0160-X" @default.
- Q37653417 P433 "1" @default.
- Q37653417 P478 "17" @default.
- Q37653417 P50 Q96141666 @default.
- Q37653417 P577 "2016-12-19T00:00:00Z" @default.
- Q37653417 P6216 Q50423863 @default.
- Q37653417 P698 "27995532" @default.
- Q37653417 P932 "5318328" @default.